Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid

PHASE4CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

February 28, 2025

Study Completion Date

March 21, 2025

Conditions
Osteogenesis Imperfecta
Interventions
DRUG

Teriparatide Pen Injector

DRUG

Zoledronic Acid

Any brand or preparation may be used to deliver the required dose of 5mg

Trial Locations (23)

4

St Vincent's Hospital, Dublin

AB25 2ZR

Aberdeen Royal Infirmary, Aberdeen

BT12 6BA

Royal Victoria Hospital, Belfast

B15 2TH

Queen Elizabeth Hospital, Birmingham

NS2 8HW

Bristol Royal Infirmary, Bristol

CB2 0QQ

Addenbrooke's Hospital, Cambridge

DD1 9SY

Ninewells Hospital, Dundee

EH4 2XU

Western General Hospital, Edinburgh

G51 4TF

Queen Elizabeth University Hospital, Glasgow

LE1 5WW

Leicester Royal Infirmary, Leicester

L7 8XP

Royal Liverpool Hospital and Aintree Hospital, Liverpool

CF64 2XX

Llandough University Hospital, Llandough

SE1 9RT

Guy's and St Thomas' Hospital, London

M13 9WL

Manchester Royal Infirmary, Manchester

PS4 3BW

James Cook University Hospital, Middlesbrough

NE7 7DN

Freeman Hospital, Newcastle upon Tyne

NG5 1PD

Nottingham City Hospital, Nottingham

OX3 7HE

Nuffield Orthopaedic Centre, Oxford

S5 7AU

Northern General Hospital, Sheffield

S016 6YD

University Hospital Southampton, Southampton

HA7 4LP

Royal National Orthopaedic Hospital, Stanmore

ST6 7AG

Haywood Community Hospital, Stoke-on-Trent

ML2 0DP

Wishaw General Hospital, Wishaw

All Listed Sponsors
collaborator

NHS Lothian

OTHER_GOV

lead

University of Edinburgh

OTHER

NCT03735537 - Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid | Biotech Hunter | Biotech Hunter